Caribou Biosciences, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Caribou Biosciences, Inc. (CRBU) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.80 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.80, a 25.87% increase year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.43, a 78.66% decline year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $6.70, a 10.56% increase year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $6.06, a 42.12% decline year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.59, a 73.05% decline from fiscal 2024.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $5.90, a 3.51% increase from fiscal 2023.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.70, a 35.30% decline from fiscal 2022.
- Caribou Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $8.81, a 19.84% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.80 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | $1.80 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $1.59 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $1.59 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $1.43 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $1.43 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $5.90 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $5.97 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $6.44 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $6.70 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $5.70 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $5.74 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $5.79 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $6.06 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $8.81 10-K · filed 2024-03-11 | |||
| 2022-09-30 | $8.88 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $8.56 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $10.47 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $10.99 10-K · filed 2023-03-09 | |||
| 2021-09-30 | $6.99 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $5.27 10-Q · filed 2021-09-02 | |||
| 2021-03-31 | $4.11 10-Q · filed 2021-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |